Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

NCT00158782 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: GW786034
DRUG: lapatinib

Sponsor

GlaxoSmithKline